Journal of Molecular Catalysis B: Enzymatic p. 143 - 153 (2014)
Update date:2022-08-16
Topics:
Le Joubioux, Florian
Bridiau, Nicolas
Sanekli, Mehdi
Graber, Marianne
Maugard, Thierry
Ceramides are spingolipid compounds that are very attractive as active components in both the pharmaceutical and the cosmetic industries. In this study, the synthesis of ceramide analogs, the so-called pseudo-ceramides, was carried out using for the first time a two-step continuous enzymatic process with immobilized Candida antarctica lipase B (Novozym435) in a packed-bed bioreactor. The first step involved the selective N-acylation of 3-amino-1,2-propanediol using stearic acid as the first acyl donor (i). This was followed by the selective O-acylation of the N-stearyl 3-amino-1,2-propanediol synthesized in the first step, with myristic acid as the second acyl donor, to produce a N,O-diacyl 3-amino-1,2-propanediol-type pseudo-ceramide, namely 1-O-myristyl,3-N-stearyl 3-amino-1,2-propanediol (ii). The process was first optimized by evaluating the influences of three factors: feed flow rate, quantity of biocatalyst and substrate concentration. Under optimal conditions an amide synthesis yield of 92% and a satisfying production rate of almost 3.15 mmol h-1gbiocatalyst-1(1128 mg h-1gbiocatalyst-1) were obtained. The second step, N-acyl 3-amino-1,2-propanediol O-acylation, was similarly optimized and in addition the effect of the substrate molar ratio was studied. Thus, an optimal pseudo-ceramide synthesis yield of 54% and a production rate of 0.46 mmol h-1gbiocatalyst-1(261 mg h-1gbiocatalyst-1) were reached at a 1:3 ratio of amide to fatty acid. In addition, it was demonstrated that this two-step process has great potential for the production of N,O-diacyl 3-amino-1,2-propanediol-type pseudo-ceramides on an industrial scale. It was shown in particular that Novozym435 could be used for more than 3 weeks without a drop in the yield during the first step of 3-amino-1,2-propanediol N-acylation, proving that this biocatalyst is very stable under these operational conditions. This factor would greatly reduce the need for biocatalyst replacement and significantly lower the associated cost.
View MoreContact:+44 (0)2036089360-31
Address:Chanceryhouse,Chancery Lan
Suzhou Chiral Pharmaceuticals Co., Ltd.
Contact:86-0512-63197058
Address:Building A, No. 2358, Chang'an Road, Wujiang Science Park
Shijiazhuang City Xiehe Pharmaceutical Co., Ltd
Contact:+86-311-80817929
Address:Shangzhuang,Shijiazhuang,China
ZHEJIANG CHEMICAL INDUSTRY INSTITUTE TECHNOLOGY CO.,LTD
Contact:86-575-82730298
Address:shangyu
Tianjin Crest Pharmaceutical R&D Co., Ltd. (Tianjin Yao Technology Development Co., Ltd.)
Contact:+86-22-66211386
Address:Building B5-405, No, 80 4th Avenue, TEDA, Tianjin, China P.R. 300457
Doi:10.1016/S0040-4020(00)00565-2
(2000)Doi:10.1021/jm970590k
(1998)Doi:10.1080/00304948.2018.1525673
(2018)Doi:10.1016/0040-4039(96)00627-2
(1996)Doi:10.1039/c9ra03498f
(2019)Doi:10.1016/0921-4534(96)00314-0
(1996)